购物车
您的购物车当前为空
TNCA
Synonyms: Lycoperodine-1, (S)-2,3,4,9-四氢-1H-吡啶[3,4-B]吲哚-3-羧酸货号 T7716Cas号 42438-90-4 一键复制产品信息纯度: 97.73%
很棒
很棒TNCA (Lycoperodine-1) 是一种具有共激动剂活性的高亲和力 CaSR 配体 (CaSRL)。
TNCA
一键复制产品信息 很棒纯度: 97.73%
货号 T7716Cas号 42438-90-4
别名 Lycoperodine-1, (S)-2,3,4,9-四氢-1H-吡啶[3,4-B]吲哚-3-羧酸
TNCA (Lycoperodine-1) 是一种具有共激动剂活性的高亲和力 CaSR 配体 (CaSRL)。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 10 mg | ¥ 129 | 现货 | |
| 25 mg | ¥ 263 | 现货 | |
| 50 mg | ¥ 423 | 现货 | |
| 100 mg | ¥ 653 | 现货 | |
| 500 mg | ¥ 1,660 | 现货 |
库存状态实时更新，以官网显示为准，现货产品可直接加购物车下单
大包装 & 定制
加入购物车
TargetMol的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。
产品介绍
TNCA AI Summary
TNCA displays notable bioactivity across several domains, primarily showing significant inhibitory effects on platelet aggregation and thrombus formation. In vitro studies using rabbit blood reveal that it notably affects platelet aggregation induced by adenosine diphosphate (ADP) and platelet activating factor (PAF) at varying doses. This compound also impacts the adhesion of high pulmonary metastatic SACC-LM cells and platelets, alongside reducing wet and dry thrombus weights in male Wistar anesthetized rats.
Furthermore, in pig blood assays, TNCA demonstrates inhibitory activity on several platelet aggregation pathways, with IC50 values approximate to 3300 nM for ADP, arachidonic acid, PAF, and thrombin-induced platelet aggregation, suggesting potential as an antiplatelet agent. It exhibits effective antithrombotic activity in the Wistar rat arteriovenous cannula model, reducing thrombus weight at a dose of 5 umol/kg, iv.
Beyond its antiplatelet properties, TNCA also shows anti-inflammatory potential by inhibiting iNOS-mediated nitric oxide production in LPS-stimulated mouse RAW 264.7 cells and TNF-alpha-induced NFkappaB activation in human HEK293 cells. It enhances quinone reductase 1 activity in mouse Hepa-1c1c7 cells and inhibits aromatase activity, reflecting potential cytoprotective and enzyme inhibitory functions. Additionally, its antioxidant capability is indicated by a trolox equivalents ratio of 1.68 in the ABTS radical scavenging assay.
Overall, the multifaceted bioactivity profile of TNCA suggests significant therapeutic potential across antiplatelet, antithrombotic, anti-inflammatory, cytoprotective, and antioxidant domains..
Note: Summary generated by AI. Data source: ChEMBL 
生物活性
化学信息
储存&溶解度
| 产品描述 | TNCA (Lycoperodine-1) is a high-affinity CaSR ligand (CaSRL) with co-agonist activity. |
| 别名 | Lycoperodine-1, (S)-2,3,4,9-四氢-1H-吡啶[3,4-B]吲哚-3-羧酸 |
| 分子量 | 216.24 |
| 分子式 | C12H12N2O2 |
| CAS No. | 42438-90-4 |
| Smiles | OC(=O)[C@@H]1Cc2c(CN1)[nH]c1ccccc21 |
| 密度 | 1.377g/cm3 |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 | ||||||||||||||||||||
| 溶解度信息 | DMSO: < 2.16 mg/mL (10 mM, insoluble or slightly soluble)  | ||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||
DMSO
该溶液配制表仅适用于固体产品。对于液体产品，请根据标明的浓度或密度计算稀释方案。 | |||||||||||||||||||||
计算器
体内实验配液计算器
请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：
比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL， 一共给药动物10只，您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O， 那么您的工作液浓度为2 mg/mL。
母液配置方法：2 mg 药物溶于 100 μL DMSO （ 母液浓度为 20 mg/mL ）, 如您需要配置的浓度超过该产品的溶解度，请先与我们联系。
体内配方的制备方法： 取 100 μL DMSO 母液， 添加 400 μL PEG300 混匀澄清， 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例，并不是具体某个化合物的推荐配制方式，请根据您的实验动物和给药方式选择适当的溶解方案。
剂量转换
对于不同动物的给药剂量换算，您也可以参考 更多
关键词
预览
Related Tags: buy TNCA | purchase TNCA | TNCA cost | order TNCA | TNCA chemical structure | TNCA formula | TNCA molecular weight
嗨！有任何问题？点我咨询
版权所有©2015-2026 TargetMol Chemicals Inc.保留所有权利.
沪ICP备20019793号-4 | 沪公网安备 31010602006700号
| 沪(静)应急管危经许[2024]203441